Drug Trial Radar · NCT07107672
Mass Balance Study of [14C]X842 in Healthy Adult Male Subjects
Last checked: Nov 20, 2026Latest source record: Aug 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Jun 15, 2022
Primary completion
Jul 7, 2022
Study completion Nov 14, 2022
Sponsor
- Lead sponsor
- Jiangsu Sinorda Biomedicine Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Aug 6, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Basic science
- FDA-regulated drug
- No
- Who can join
- Male only, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a single-site, single-dose, non-randomized, open-label study to assess the absorption, metabolism, and excretion profile of \[14C\]X842 in healthy adult male subjects. The study plans to enroll 6 to 8 healthy male subjects in China to ensure at least 4 evaluable subjects.
Conditions
- Gastroesophageal Reflux Disease
Interventions
[14C]X842Drug
50 mg/100 µCi \[14C\] X842 suspension
Primary outcomes
What the sponsor says the trial is designed to measure.
- Mass balance: the cumulative excretion rateTime frame: 22 days
- Tmax (time to maximum observed concentration)Time frame: 22 days
- Cmax(maximum concentration)Time frame: 22 days
- AUC(area under curve)Time frame: 22 days
- t1/2 (terminal elimination half-life)Time frame: 22 days
- MRT (mean residence time)Time frame: 22 days
- Vd/F(apparent volume of distribution)Time frame: 22 days
- whole blood/plasma ratio for the total radioactivity concentration at different time pointsTime frame: 22 days
- Percentage of the drug and its metabolites in plasma, urine and feces to the administered doseTime frame: 22 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Bengbu Medical College
Bengbu, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.